(Q36914988)

17 August 2017

1 reference

title

Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy (English)

1 reference

17 August 2017

anti-retroviral agent

0 references

author name string

Julian Falutz

series ordinal

1

1 reference

17 August 2017

1 September 2007

1 reference

Nature Clinical Practice Endocrinology and Metabolism

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

9

1 reference

17 August 2017

651-661

1 reference

Alterations in lipid kinetics in men with HIV-dyslipidemia.

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

Management of HIV wasting syndrome: a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Coronary lesions in young HIV-positive subjects at necropsy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Fat distribution in men with HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The perils of portliness: causes and consequences of visceral adiposity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

HIV-associated lipodystrophy syndrome: A review of clinical aspects

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metabolic complications of HIV therapy in children.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

A common mitochondrial DNA variant is associated with insulin resistance in adult life.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mitochondrial dysfunction in multiple symmetrical lipomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Atazanavir: new option for treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

1 reference

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

HIV envelope gp120 activates human arterial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metabolic syndrome: a multiplex cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The metabolic syndrome: is this diagnosis necessary?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Prevalence and trends of a metabolic syndrome phenotype among u.s. Adolescents, 1999-2000.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: can we afford to be sedentary and unfit?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compart

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

HIV/AIDS epidemiology, pathogenesis, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Select HIV protease inhibitors alter bone and fat metabolism ex vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0587

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0587

1 reference

17 August 2017

1 reference

PubMed ID

17710086